INmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor™ for Pulmonary Complica...

INmune Bio, Inc. Announces Third Quarter Results and Provides Business Update...

INmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Th...

INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s...

INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, Se...

INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase ...

INmune Bio, Inc. to Participate in Oppenheimer’s Fall Healthcare Life Science & Med Tech Virtu...

INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmu...

INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor™ in a Blinded Ran...

European Patent Granted Covering INmune Bio’s XPro1595...

INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update...

INmune Bio, Inc to Present at the BTIG Virtual Biotechnology Conference 2020...

INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results...

INmune Bio, Inc. Featured on Fox News (VIDEO): STNF and Cytokine Storm...

Correction: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Includ...

INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exe...

INmune Bio, Inc. Prices Public Offering of Common Stock...

INmune Bio, Inc. Announces Proposed Public Offering of Common Stock...

INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflamma...

INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with ...

INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in P...

Killers at the Crossroad – A Published Review of Innate Immune Cell Potential in Treatment of Canc...

INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update...

INmune Bio Inc’s INB03 Inhibits Cell Migration, Tumor Growth, and Induces Innate Immune Response i...

INmune Bio, Inc. to Host First Quarter 2020 Earnings Conference Call...

INmune Bio, Inc. to Speak on COVID-19 Therapeutic Panel at Maxim Group’s Infectious Disease Virtua...

Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF’s Impact on Breast Canc...

INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming...

INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the ...

INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now In...

INmune Bio, Inc. to Present at the 32nd Annual ROTH Conference on March 17...

INmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Res...

INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immun...

INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Ris...